Overview

  • Product name

    Glucagon (19-29) (human), Ca2+/Mg2+-ATPase inhibitor
  • Description

    C-terminal fragment of Glucagon. Potent Ca2+/Mg2+-ATPase inhibitor.
  • Alternative names

    • Miniglucagon
  • Biological description

    C-terminal fragment of Glucagon. Potently inhibits secretagogue-induced insulin secretion in β-cells (IC50 < 1 pM) and Ca2+/Mg2+-ATPase activity in liver plasma membranes (IC50 = 0.75 nM). May also contribute to the positive inotropic effect of glucagon in cardiac cells by amplifying the cytosolic Ca2+ signal.
  • Purity

    > 95%
  • CAS Number

    64790-15-4
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Dalle S  et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes 51:406-12 (2002). Read more (PubMed: 11812748) »
  • Dalle S  et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem 274:10869-76 (1999). Read more (PubMed: 10196164) »
  • Blache P  et al. Endopeptidase from rat liver membranes, which generates miniglucagon from glucagon. J Biol Chem 268:21748-53 (1993). Read more (PubMed: 8408029) »
  • Pavoine C  et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol 260:C993-9 (1991). Read more (PubMed: 1852111) »
  • Mallat A  et al. A glucagon fragment is responsible for the inhibition of the liver Ca2+ pump by glucagon. Nature 325:620-2 (0). Read more (PubMed: 2949156) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142303.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up